

Supplemental Information for “*Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences,*” by McPartland, Glass, Pertwee

Table S-6

Rank order of ligand affinity reported in studies that examined ≥2 ligands per receptor, measured by displacement of [³H]CP55,940 or other tritiated agonists as described in footnotes¹

	reference, notes ²	rank order ³
CB1	Devane et al., 1988; [³ H]CP, nativeC, ØPMSF	RnCB1: CP(0.68) > THC(1.6) > CBN(13) > CBD(>500)
CB1	Bridgen et al., 1990; [³ H]CP, nativeC, ØPMSF	RnCB1: HU(0.68) > CP(0.78) » THC(143.4)
CB1	Herkenham et al., 1990; [³ H]CP, nativeA, ØPMSF	RnCB1: CP(15) » THC(420) » CBN(3200) » CBD(53,000)
CB1	Devane et al., 1992; [³ H]HU, nativeB, ØPMSF	RnCB1: HU(0.234) > CP(2.0) » THC(46)
CB1	Felder et al., 1992; [³ H]CP, CB1trans5, ØPMSF	HsCB1: CP(3.72) » THC(53.3) » WIN(564)
CB1	Jansen et al., 1992; [³ H]CP, nativeD, ØPMSF	RnCB1: CP(1.0) > WIN(8.8)
CB1	Thomas et al., 1992; [³ H]THC-DMH, nativeF, ØPMSF	RnCB1: CP(52) > WIN(522) » THC(2200)
CB1	Compton et al., 1993; [³ H]CP, nativeC, ØPMSF	RnCB1: HU(0.73) ≈ CP(0.92) » THC(40.7) » CBD(4350)
CB1	Houston + Howlett, 1993; [³ H]CP, nativeC, ØPMSF	RnCB1: CP(0.94) » THC(24.1) > CBN(159) » CBD(3000)
CB1	Abadji et al., 1994; [³ H]CP, nativeC, +PMSF	RnCB1: MethAEA(20) » AEA(78)
CB1	Childers et al., 1994; [³ H]WIN, nativeD, +PMSF	RnCB1: WIN(0.3) » AEA(60.4)
CB1	Rinaldi-Carmona et al., 1994; [³ H]CP, CB1nativeC, CB2nativeJ	RnCB1: CP(1.37) ≈ SR(1.98) > WIN(9.94) > THC(35.3)
CB1	Vogel et al., 1994 [³ H]HU, trans3, ØPMSF, Centri	RnCB1: AEA(155) > CBN(1336)
CB1	Adams et al., 1995; [³ H]CP, nativeB ØPMSF	RnCB1: CP(0.58) » MethAEA(87) » AEA(89)
CB1	Bouabola et al., 1995; [³ H]CP, trans2, ØPMSF	HsCB1: CP(0.68) > THC(3.9) » WIN(485)
CB1	Felder et al., 1995; [³ H]CP, CB1trans5, CB2trans1, +PMSF	HsCB1: HU(0.06) » CP(3.72) » THC(53.3) ≈ WIN(62.3) > AEA(543) > CBN(1130)
CB1	Hillard et al., 1995; [³ H]CP, nativeC, +PMSF	RnCB1: CP(0.7) > THC(52) > AEA(143)
CB1	Welch et al., 1995; [³ H]CP, native spinal cord, +PMSF	RnCB1: CP(0.9) > AEA(214) > THC(300)
CB1	Mechoulam et al., 1995; [³ H]HU, CB1nativeB, CB2trans3, ØPMSF	RnCB1: AEA(252) > 2AG(472)

CB1	Sugiura et al., 1995; [³ H]CP, nativeC, +DPFP	<i>RnCB1</i> : CP(0.83) » AEA(89) » 2AG(2400)
CB1	Hirst et al., 1996; [³ H]SR, nativeD, +PMSF,	<i>RnCB1</i> : SR(4) > WIN(18) > THC(51) > AEA(550)
CB1	Rinaldi-Carmona et al., 1996; [³ H]SR, nativeB, ØPMSF	<i>RnCB1</i> : SR(1.35) > CP(8.1) > WIN(39.4) ≈ THC(40.5) > AEA(152.9)
CB1	Rinaldi-Carmona et al., 1996 [³ H]CP, trans3, ØPMSF	<i>HsCB1</i> : CP(2.26) > SR(4.9) > THC(7.1) » WIN(93) > AEA(298)
CB1	Showalter et al., 1996; [³ H]CP, trans2, +PMSF	<i>HsCB1</i> : CP(0.58) > SR(12.3) > THC(21) » CBN(326)
CB1	Song + Bonner, 1996; [³ H]WIN, trans4, ØPMSF	<i>HsCB1</i> : HU(0.26) » CP(4.6) > WIN(11.9) > AEA(115.6)
CB1	Deutsch et al., 1997; [³ H]AEA, renal epithelium	<i>HsCB1</i> : CP(28.1) > AEA(29.5) > SR(31.5) > SR(41.6)
CB1	Gatley et al., 1997; [³ H]CP, nativeD, ØPMSF	<i>MmCB1</i> : CP(0.9) » WIN(12) > SR(16) > THC(131)
CB1	Gifford et al., 1997 [³ H]SR, nativeE	<i>RnCB1</i> : SR(2) » WIN(170) » THC(1700)
CB1	Rhee et al., 1997; [³ H]HU, CB1nativeB and trans3, CB2trans3, ØPMSF	<i>RnCB1nativeB</i> : HU(0.19) » THC(66.5) » CBN (392) <i>RnCB1trans3</i> : HU(0.1) » THC(80.3) » CBN (211.2)
CB1	Sheskin et al., 1997; [³ H]HU, nativeB, ØPMSF	<i>RnCB1</i> : methAEA(31.1) > AEA(39.2) > THC(46)
CB1	Berglund et al., 1998; [³ H]CP, <i>RnCB1nativeA</i> , <i>HsCB2nativeL</i> +PMSF	<i>RnCB1</i> : methAEA (3.2) > AEA(12)
CB1	Bonhaus et al., 1998; [³ H]CP, trans2, ØPMSF, Log	<i>HsCB1</i> : HU(0.63) > CP(3.0) » THC(32) = WIN(32) » AEA(631)
CB1	Chin et al., 1998; [³ H]CP, trans2, ØPMSF	<i>HsCB1</i> : CP(7.7) > WIN(16.2)
CB1	Lin et al., 1998; [³ H]CP, CB1nativeC, +PMSF	<i>RnCB1</i> : methAEA(17.9) > AEA(61.0)
CB1	MacLennan et al., 1998; [³ H]CP, trans2, +PMSF, Log	<i>HsCB1</i> : CP(2) > SR(17) > WIN(42) > CBN(120)
CB1	Rinaldi-Carmona et al., 1998 [³ H]CP for CP, [³ H]SR for SR, trans2, ØPMSF	<i>HsCB1</i> : SR(4.84) > CP(5.47)
CB1	Tao + Abood, 1998; [³ H]CP trans4, +PMSF	<i>HsCB1</i> : HU(0.44) > SR(0.68) > CP(1.21) » WIN(17.4) > THC(33.6) > AEA(321)
CB1	Thomas et al., 1998; [³ H]CP, nativeB, +PMSF	<i>RnCB1</i> : CP(0.54) > WIN(2.48) > SR(6.18) > AEA(29.7) ≈ THC(37.0) > CBN(247) » CBD(2283)
CB1	Chin et al., 1999; [³ H]CP, trans2, ØPMSF	<i>HsCB1</i> : CP(3.8) > SR(5.9) > WIN(21.7) > methAEA(35.1)
CB1	Hillard et al., 1999; [³ H]CP, nativeD, nativeJ +PMSF	<i>RnCB1</i> : CP(0.5) > WIN(4.4) » AEA(71.7)
CB1	Kanyonyo et al., 1999 [³ H]SR, trans2	<i>HsCB1</i> : HU(0.82) > CP(5.2) > SR(8.9) » WIN(152.2)
CB1	Kathmann et al., 1999 [³ H]SR, nativeC, Log	<i>RnCB1</i> : SR(2.95) » CP(45.7) > WIN(1174)
CB1	Kearn et al., 1999; [³ H]CP, nativeD, +PMSF	<i>RnCB1</i> : HU(0.09) > CP(0.58) > WIN(4.4) > THC(28.4) > AEA(71.7)
CB1	Song et al., 1999; [³ H]CP, trans4, ØPMSF	<i>HsCB1</i> : HU(0.21) » CP(2.2) » WIN(25.4) > AEA(76.2)
CB1	Breivogel + Childers, 2000 [³ H]SR, nativeD, nativeE,	<i>HsCB1</i> (cerebellum): CP(1.7) > WIN(11) > THC(210) > metA(150)

	native hypothalamus	<i>HsCB1(hippocampus): CP(5.6) > WIN(29) > THC(170) > metA(330)</i> <i>HsCB1(hypothalamus): CP(2.0) > WIN(14) > THC(37) > metA(240)</i>
CB1	Fowler et al., 2001; [³ H]SR, nativeB, ØPMSF	<i>RnCB1: SR(0.57) > CP(8.44) > WIN(194.9) > AEA(240)</i>
CB1	Iwamura et al., 2001; [³ H]CP, <i>HsCB1+CB2 trans2</i> , <i>RnCB1+CB2 nativeD+nativeK</i> , ØPMSF	<i>HsCB1: THC(5.05) > WIN (9.87)</i> <i>RnCB1: WIN (0.14) » THC(13.5)</i> <i>MmCB1: WIN(0.41) » THC(8.33)</i>
CB1	Devlin+Christopoulos, 2002 [³ H]SR, nativeD, Log	<i>RnCB1: HU(0.32) > CP(1.26) > SR(2.24) > WIN(6.31)</i>
CB1	Lichtman et al., 2002; [³ H]CP, nativeC, +PMSF	<i>MmCB1: CP(0.49) » AEA(61) > MethAEA(75) » 2AG(1890)</i>
CB1	Mauler et al., 2002; [³ H]BAY, <i>HsCB1trans0</i> , <i>HsCB1nativeC</i> , <i>RnCB1nativeC</i> , <i>HsCB2trans0</i> , ØPMSF	<i>HsCB1trans0: HU(0.41) > CP(1.10) > WIN(11.7) > THC(15.3)</i> <i>HsCB1nativeC: CP(0.51) > THC(13.7)</i> <i>RnCB1: HU(0.39) > CP(1.30) > WIN(6.87) > THC(77.3)</i>
CB1	McAllister et al., 2002; [³ H]CP, trans4, +PMSF	<i>HsCB1: WIN(1.3) > SR(7.1) > THC(37) » AEA(450)</i>
CB1	van der Stelt et al., 2002 [³ H]CP, nativeC +PMSF	<i>RnCB1: AEA(90) ≈ 2-AG(100)</i>
CB1	Marchese et al., 2003; [³ H]CP, nativeD	<i>RnCB1: CP(0.32) » THC(21.3)</i>
CB1	McAllister et al., 2003; [³ H]CP, <i>MmCB1</i> , trans4, +PMSF	<i>MmCB1: SR(4.8) > WIN(12) » AEA(300)</i>
CB1	De Vry et al., 2004; [³ H]BAY, <i>CB1nativeC</i> , <i>CB2trans0</i> ØPMSF	<i>HsCB1: CP(0.51) > 13.7(THC)</i> <i>RnCB1: CP(1.15) » THC(69.7)</i>
CB1	Govaerts et al., 2004 trans2, <i>CB1:[³H]CP</i> ; <i>CB2:[³H]WIN</i> , ØPMSF	<i>HsCB1: HU(1.7) > CP(6.6) > THC(32.4) > SR(33.1) > WIN(129)</i> <i>MmCB1: CP(0.30) ≈ HU(0.32) » WIN(7.1) ≈ SR(9.3) » THC(98)</i>
CB1	Steffens et al., 2004; [³ H]CP, nativeC, nativeAmygdala, +PMSF	<i>HsCB1(neocortex): CP(2.14) > THC(19.5) > AEA(25.7) > WIN(53.7)</i> <i>HsCB1(amygdala): CP(2.29) > THC(17.8) > WIN(40.7) > AEA(54.0)</i>
CB1	Brizzi et al., 2005; [³ H]CP, trans3, ØPMSF	<i>HsCB1: WIN(21) > AEA(72)</i>
CB1	Bobrov et al., 2005 [³ H]CP <i>HsCB1+2 trans2</i> , <i>RnCB1+2 nativeC+nativeJ</i> , ØPMSF	<i>HsCB1: CP(0.31) » 2-AG(160) > AEA(240)</i> <i>RnCB1: CP(0.09) » AEA(160) > 2-AG(26% at 1000)</i>
CB1	Muccioli et al., 2005 [³ H]SR; trans2	<i>HsCB1: SR(5.4) > HU(18.6) » WIN(3802)</i>
CB1	Picone et al., 2005; [³ H]CP, trans2, ØPMSF	<i>HsCB1: CP(6.7) > WIN(18.3) > THC(89.9)</i>
	Ryberg et al., 2005; [³ H]CP, trans4, ØPMSF	<i>HsCB1: HU(0.15) > CP(2.53) ≈ THC(3.17) ≈ SR(3.27) > WIN(13.7) > AEA(24.4) > 2AG(110.7)</i>
CB1	Shoemaker et al., 2005; [³ H]CP, <i>CB1nativeD</i> , <i>CB2trans2</i>	<i>RnCB1: CP(0.55) » 2-AG(1750)</i>
CB1	Steffens et al., 2005; [³ H]CP, nativeC, +PMSF	<i>HsCB1: AEA(25.7) » 2AG(»10000)</i>

CB1	Valenzano et al., 2005; [³ H]CP, <i>HsCB1+CB2 trans2</i>	<i>HsCB1</i> : CP(2.84) > WIN(106.9)
CB1	D'Antona et al., 2006; [³ H]CP, trans4, +PMSF	<i>HsCB1</i> : HU(3.4) > CP(4.6) > SR(7.5) > AEA(26) > WIN(73)
CB1	Shen et al., 2006; [³ H]CP, trans2, ØPMSF	<i>HsCB1</i> : HU(0.025) > CP(0.047) > WIN(1.64)
CB2	Bouaboula et al., 1993; [³ H]CP, nativeH, ØPMSF	<i>HsCB2</i> : CP(0.062) > THC(0.07) > WIN(16.14)
CB2	Munro et al., 1993; [³ H]CP, trans3, ØPMSF	<i>HsCB2</i> : CP(1.6) > WIN(3.7) > CBN(250) > THC(320) > AEA(1600) ³ » CBD(38000)
CB2	Rinaldi-Carmona et al., 1994; [³ H]CP, CB1nativeC, CB2nativeJ	<i>RnCB2</i> : CP(1.37) > THC(3.90) > WIN(16.2) » SR(1000)
CB2	Lynn + Herkenham, 1994; [³ H]CP, nativeJ, ØPMSF	<i>RnCB2</i> : CP(7.2) » THC(700) » CBD(41,800)
CB2	Bayewitch et al., 1995 [³ H]HU, trans2, ØPMSF	<i>HsCB2</i> : HU(0.15) » THC(39) > AEA(85)
CB2	Facci et al., 1995; [³ H]WIN, nativeN, ØPMSF	<i>RnCB2</i> : AEA(29.9) ≈ WIN(33.5) > THC(202) > CBD(>1000)
CB2	Felder et al., 1995; [³ H]CP, CB1trans5, CB2trans1, +PMSF	<i>HsCB2</i> : HU(0.52) > CP(2.55) ≈ WIN(3.30) » THC(75.3) > CBN(301) > AEA(1940)
CB2	Mechoulam et al., 1995; [³ H]HU, CB1nativeB, CB2trans3, ØPMSF	<i>HsCB2</i> : AEA(581) > 2AG(1400)
CB2	Slipetz et al., 1995; [³ H]WIN, trans3, ØPMSF	<i>HsCB2</i> : HU(0.36) > CP(1.0) ≈ WIN(1.5) » THC(24.7 > AEA(90.3)
CB2	Schatz et al., 1997; [³ H]CP, <i>MmCB2</i> , nativeK, ØPMSF	<i>MmCB2</i> : CP(1.9) ≈ CBN(2.3) > WIN(6.8) > THC(11.8)
CB2	Bouaboula et al., 1996; [³ H]CP, trans2, ØPMSF	<i>HsCB2</i> : CP(4) > WIN (22)
CB2	Shire et al., 1996; [³ H]CP, trans3, ØPMSF	<i>HsCB2</i> : CP(2.4) > WIN(3.7) > THC(16.0) » AEA(239) » SR(>1000) <i>MmCB2</i> : CP(5.6) > THC(15.8) > WIN(29.5) > AEA(326) > SR(>1000)
CB2	Showalter et al., 1996; [³ H]CP, trans2, +PMSF	<i>HsCB2</i> : HU(0.22) ≈ WIN(0.28) > CP(0.69) » THC(36.4) > CBN(96.3) > AEA(371) > SR(702) > CBD(2860)
CB2	Rhee et al., 1997; [³ H]HU, CB2trans3, ØPMSF	<i>HsCB2</i> : HU(0.17) » THC(32.2) > CBN(126.4)
CB2	Berglund et al., 1998; [³ H]CP, <i>RnCB1nativeA</i> , <i>HsCB2nativeL</i> +PMSF	<i>HsCB2</i> : methAEA(26) > AEA(67)
CB2	Lin et al., 1998; [³ H]CP, CB1nativeC, +PMSF	<i>RnCB1</i> : methAEA(868) > AEA(1930)
CB2	MacLennan et al., 1998; [³ H]CP, trans2, +PMSF, Log	<i>HsCB2</i> : CP(2) ≈ WIN(2) > CBN(10) » SR(302)
CB2	Nowell et al., 1998; [³ H]CP, trans7, ØPMSF	<i>HsCB2</i> : CP(2.24) > WIN(7.15)
CB2	Tao + Abood, 1998; [³ H]CP trans4, +PMSF	<i>HsCB2</i> : WIN(0.14) > HU(0.38) > CP(0.88) > THC(44.9)

CB2	Chin et al., 1999; [³ H]CP, trans2, ØPMSF	<i>Hs</i> CB2: WIN(2.3) > CP(4.2)
CB2	Lambert et al., 1999; <i>Hs</i> CB2trans2, [³ H]WIN, ØPMSF <i>Rn</i> CB2nativeJ, [³ H]CP, +PMSF	<i>Hs</i> CB2: WIN(10.2) > CP(19.8) » AEA(>1000) = SR(>1000) <i>Rn</i> CB2: WIN(37) » AEA(430) > methAEA(>1000) = SR(>1000)
CB2	Song et al., 1999; [³ H]CP, trans4, ØPMSF	<i>Hs</i> CB2: HU(0.19) > WIN(1.6) ≈ CP(2.4) » AEA(131.2)
CB2	Tao et al., 1999; [³ H]CP or [³ H]WIN, trans4, ØPMSF	<i>Hs</i> CB2: CP(0.75) ≈ WIN(0.91) » THC(44.9) > CBN(92.7) > AEA(306)
CB2	Gonsiorek et al., 2000; [³ H]CP, trans2 + trans7, +PMSF	<i>Hs</i> CB2 trans2: HU(0.83) » AEA(348) > 2AG(474) <i>Hs</i> CB2 trans7: HU(2.3) » 2AG(795) > AEA(949)
CB2	Griffin et al., 2000; [wrong rat sequence], [³ H]CP, trans4, +PMSF	<i>Hs</i> CB2: CP(0.88) > WIN(1.19) » THC(44.9) » AEA (306) <i>Rn</i> CB2: CP(0.64) > WIN(10.4) » THC(28.3) » AEA (>10,000) <i>Mm</i> CB2: CP(0.73) > WIN(9.46) » THC(27.3) » AEA (>1480)
CB2	Rhee et al., 2000; [³ H]HU, trans3, ØPMSF	<i>Hs</i> CB2: HU(0.16) > WIN(1.0) > CP(5.9)
CB2	Rhee et al., 2000 ; [³ H]HU, trans3, ØPMSF	<i>Hs</i> CB2: HU(0.15) > WIN(1.0)
CB2	Feng + Song, 2001; [³ H]HU, trans4, ØPMSF	<i>Hs</i> CB2: HU(0.47) > WIN(3.4) > AEA(314.5)
CB2	Iwamura et al., 2001; [³ H]CP, <i>Hs</i> CB1+CB2 trans2, <i>Rn</i> CB1+CB2 nativeD+nativeK, ØPMSF	<i>Hs</i> CB2: WIN(0.29) » THC(3.13) <i>Rn</i> CB2: WIN(1.30) > THC(6.80) <i>Mm</i> CB2: WIN(0.56) > THC(1.73)
CB2	Mauler et al., 2002; [³ H]BAY, <i>Hs</i> CB2trans0, ØPMSF	<i>Hs</i> CB2: HU(0.14) > WIN(0.41) > CP(0.52) » THC(25.06)
CB2	McAllister et al., 2002; [³ H]CP, trans4, +PMSF	<i>Hs</i> CB2: WIN(1.0) » THC(33) » AEA(188)
CB2	Song + Feng, 2002; [³ H]WIN, trans4, ØPMSF	<i>Hs</i> CB2: HU(0.62) > WIN(4.8) » AEA(687.5)
CB2	van der Stelt et al., 2002 [³ H]CP, nativeJ +PMSF	<i>Rn</i> CB2: 2-AG(100) > AEA(360)
CB2	Feng + Song, 2003 ; [³ H]HU, trans4, ØPMSF	<i>Hs</i> CB2: HU(0.47) > WIN(3.41) » AEA(314.5)
CB2	Olson et al., 2003; [³ H]CP, trans BHK cells,	<i>Mm</i> CB2: CP(0.36) > WIN(2.49)
CB2	De Vry et al., 2004; [³ H]BAY, CB2trans0, ØPMSF	<i>Hs</i> CB2: CP(0.54) » THC(22.9)
CB2	Govaerts et al., 2004; [³ H]CP, nativeJ, CB2, ØPMSF	<i>Rn</i> CB2: WIN(1.8) > CP(2.2) » HU(40) » SR(1660)
CB2	Govaerts et al., 2004; <i>Hs</i> CB2trans2 - [³ H]WIN; <i>Rn</i> CB2nativeJ - [³ H]CP; <i>Mm</i> CB2nativeJ - [³ H]CP; ØPMSF	<i>Hs</i> CB2: HU(1.5) » CP(11.2) > WIN(17) » THC(309) » SR(2138) <i>Rn</i> CB2: WIN(1.8) » HU(44.7) » SR(1622) <i>Mm</i> CB2: WIN(4.9) » HU(55) » SR(1698)
CB2	Mukherjee et al., 2004; [³ H]CP, trans4, +PMSF	<i>Hs</i> CB2: CP(0.68) > WIN(1.2) » AEA(160) » 2AG(1100) <i>Rn</i> CB2: CP(0.52) > WIN(2.1) » AEA(240) » 2-AG(3700)
CB2	Bobrov et al., 2005 [³ H]CP <i>Hs</i> CB1+2 trans2,	<i>Hs</i> CB2: CP(0.49) » AEA(290) > 2-AG(520)

	<i>Rn</i> CB1+2 nativeC+nativeJ, ØPMSF	<i>Rn</i> CB2: CP(0.17) » AEA(3000) > 2-AG(37% at 1000)
CB2	Brizzi et al., 2005; [³ H]CP, trans3, ØPMSF	<i>Hs</i> CB2: HU(0.05) > WIN(2.1)
CB2	Savinainen et al., 2005; [³ H]CP, trans2, ØPMSF	<i>Hs</i> CB2: CP(1.34) ≈ HU(1.95) > WIN(3.1) > 2AG(3500) > AEA(5100)
CB2	Shoemaker et al., 2005; [³ H]CP, CB1nativeD, CB2trans2	<i>Hs</i> CB2: CP(0.58) » 2-AG(1016)
CB2	Valenzano et al., 2005 [³ H]CP, trans2	<i>Hs</i> CB2: CP(2.33) ≈ WIN(2.37)
CB2	Lunn et al., 2006; [³ H]CP, trans7, ØPMSF	<i>Hs</i> CB2: CP(1.8) > HU(3.2) » SR(2596)

¹ a compilation of data from [Table S-1](#) and [Table S-2](#), including all studies that measured affinity of ≥2 ligands, enabling calculations of rank orders

² Ligands: THC, Δ⁹-tetrahydrocannabinol; CBD, cannabidiol; CBN, cannabinol; AEA, anandamide (*N*-arachidonoyl ethanolamine); metA, *R*-(+)-methanandamide; 2AG, *sn*-2 arachidonoyl glycerol; CP, CP55,940; WIN, WIN55212-2; HU, HU210 (11-OH-Δ⁸-THC-dimethylheptyl); SR, SR141716A. Methodological notes: radioligand used in study: [³H]CP, [³H]CP55,940; [³H]SR, [³H]SR141716A; [³H]WIN, [³H]WIN55212-2; [³H]HU, [³H]HU243; [³H]BAY, [³H]BAY38-7271; [³H]THC-DMH, [³H]11-OH-Δ⁹-THC-dimethylheptyl; [³H]AEA, [³H]anandamide. Note that HU210 is not HU243 (3-dimethylheptyl-11-hydroxyhexahydrocannabinol, namely reduced HU210, carrying no double bond), and HU210 is not equivalent to 11-OH-Δ⁹-THC-DMH. Tissues or cells used in study were native or transfected. Native included: A = brain homogenates (unspecified), B = whole brain homogenates, C = cerebrum (cortical) homogenates or ‘forebrain’ homogenates, D = cerebellum homogenates, E = hippocampus homogenates, F = cortex and caudate-putamen slices, G = neuroblastoma (*Mm* N18TG2 or N1E-115) cells, H = *Hs* monocyte (U937) cells, J = whole spleen homogenates, K = splenocyte homogenates, L = tonsil homogenates, M = leukemia cells, N = *Rn* RBL-2H3 leukemia cells. Transfected cells included: 0 = cell type not specified, 1 = AtT-20 cells, 2 = CHO cells, 3 = COS cells, 4 = HEK-293 cells, 5 = LtK cells, 6 = *Xenopus* oocytes, 7 = Sf9 cells. “+PMSF” indicates the presence of PMSF or another endocannabinoid enzyme inhibitor.

³ rank order based on Ki values (listed parenthetically, in nM units), where (≈) = Ki values within a factor of 1.5 from each other; (>) = Ki values between 1.5- and 10-fold from each other; (») = Ki values greater than 10-fold from each other. Cannabinoid abbreviations: AEA = anandamide, CBD = cannabidiol, CBN = cannabinol, CP = CP55,940, methAEA = *R*-(+)-methanandamide, HU = HU210, SR = SR141716A, THC = Δ⁹-tetrahydrocannabinol, WIN = WIN55212-2, 2AG = 2-arachidonoyl glycerol.

Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G. and Makriyannis, A. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. *J Med Chem*, **37**, 1889-93.

Adams, I. B., Ryan, W., Singer, M., Razdan, R. K., Compton, D. R. and Martin, B. R. (1995). Pharmacological and behavioral evaluation of alkylated anandamide analogs. *Life Sci*, **56**, 2041-8.

- Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R. and Vogel, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. *FEBS Lett.*, **375**, 143-7.
- Bayewitch, M., Rhee, M. H., Avidor-Reiss, T., Breuer, A., Mechoulam, R. and Vogel, Z. (1996). (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. *J Biol Chem.*, **271**, 9902-5.
- Berglund, B. A., Boring, D. L., Wilken, G. H., Makriyannis, A., Howlett, A. C. and Lin, S. (1998). Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. *Prostaglandins Leukot Essent Fatty Acids*, **59**, 111-8.
- Bobrov, M., Gretskaya, N., Payet, O., Bezuglov, V., Durand, T., Maurin, L., Tourrel, F., Adjali, O., Rinaldi-Carmona, M. and Muller, A. (2005). Different pharmacological profile of two closely related endocannabinoid ester analogs. *Life Sci.*, **77**, 1425-40.
- Bonhaus, D. W., Chang, L. K., Kwan, J. and Martin, G. R. (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. *J Pharmacol Exp Ther.*, **287**, 884-8.
- Bouaboula, M., Poinot-Chazel, C., Bourrie, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G. and Casellas, P. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. *Biochem J.*, **312 (Pt 2)**, 637-41.
- Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G. and Casellas, P. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of KroX-24 expression. *Eur J Biochem*, **237**, 704-11.
- Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G. and Casellas, P. (1993). Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem*, **214**, 173-80.
- Breivogel, C. S. and Childers, S. R. (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther.*, **295**, 328-36.
- Bridgen, T., Fan, F., Compton, D. R. and Martin, B. R. (1990). Competitive inhibition of cannabinoid binding in a novel filtration assay. *FASEB Journal*, **4**, A996.
- Brizzi, A., Brizzi, V., Cascio, M. G., Bisogno, T., Sirianni, R. and Di Marzo, V. (2005). Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. *J Med Chem.*, **48**, 7343-50.
- Childers, S. R., Sexton, T. and Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. *Biochem Pharmacol.*, **47**, 711-5.
- Chin, C. N., Lucas-Lenard, J., Abadji, V. and Kendall, D. A. (1998). Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. *J Neurochem.*, **70**, 366-73.
- Chin, C. N., Murphy, J. W., Huffman, J. W. and Kendall, D. A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. *J Pharmacol Exp Ther.*, **291**, 837-44.
- Compton, D. R., Rice, K. C., De Costa, B. R., Razdan, R. K., Melvin, L. S., Johnson, M. R. and Martin, B. R. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. *J Pharmacol Exp Ther.*, **265**, 218-26.

- D'Antona, A. M., Ahn, K. H. and Kendall, D. A. (2006). Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. *Biochemistry*, **45**, 5606-17.
- De Vry, J., Denzer, D., Reissmueller, E., Eijckenboom, M., Heil, M., Meier, H. and Mauler, F. (2004). 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. *J Pharmacol Exp Ther*, **310**, 620-32.
- Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. and Moore, L. C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. *J Clin Invest*, **100**, 1538-46.
- Devane, W. A., Breuer, A., Sheskin, T., Jarbe, T. U., Eisen, M. S. and Mechoulam, R. (1992). A novel probe for the cannabinoid receptor. *J Med Chem*, **35**, 2065-9.
- Devane, W. A., Dysarz, F. A., 3rd, Johnson, M. R., Melvin, L. S. and Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol*, **34**, 605-13.
- Devlin, M. G. and Christopoulos, A. (2002). Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. *J Neurochem*, **80**, 1095-102.
- Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D. and Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A*, **92**, 3376-80.
- Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. and Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol Pharmacol*, **48**, 443-50.
- Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M. and Matsuda, L. A. (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. *Mol Pharmacol*, **42**, 838-45.
- Feng, W. and Song, Z. H. (2001). Functional roles of the tyrosine within the NP(X)(n)Y motif and the cysteines in the C-terminal juxtamembrane region of the CB2 cannabinoid receptor. *FEBS Lett*, **501**, 166-70.
- Feng, W. and Song, Z. H. (2003). Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. *Biochem Pharmacol*, **65**, 1077-85.
- Fowler, C. J., Nilsson, O., Andersson, M., Disney, G., Jacobsson, S. O. and Tiger, G. (2001). Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain. *Pharmacol Toxicol*, **88**, 213-22.
- Gatley, S. J., Lan, R., Pyatt, B., Gifford, A. N., Volkow, N. D. and Makriyannis, A. (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. *Life Sci*, **61**, PL 191-7.
- Gifford, A. N., Tang, Y., Gatley, S. J., Volkow, N. D., Lan, R. and Makriyannis, A. (1997). Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. *Neurosci Lett*, **238**, 84-6.

- Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. and Hipkin, R. W. (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol*, **57**, 1045-50.
- Govaerts, S. J., Hermans, E. and Lambert, D. M. (2004). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. *Eur J Pharm Sci*, **23**, 233-43.
- Govaerts, S. J., Muccioli, G. G., Hermans, E. and Lambert, D. M. (2004). Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. *Eur J Pharmacol*, **495**, 43-53.
- Griffin, G., Tao, Q. and Abood, M. E. (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. *J Pharmacol Exp Ther*, **292**, 886-94.
- Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R. and Rice, K. C. (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A*, **87**, 1932-6.
- Hillard, C. J., Edgemon, W. S. and Campbell, W. B. (1995). Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. *J Neurochem*, **64**, 677-83.
- Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. and Campbell, W. B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). *J Pharmacol Exp Ther*, **289**, 1427-33.
- Hirst, R. A., Almond, S. L. and Lambert, D. G. (1996). Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. *Neurosci Lett*, **220**, 101-4.
- Houston, D. B. and Howlett, A. C. (1993). Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. *Mol Pharmacol*, **43**, 17-22.
- Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T. and Inaba, T. (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. *J Pharmacol Exp Ther*, **296**, 420-5.
- Jansen, E. M., Haycock, D. A., Ward, S. J. and Seybold, V. S. (1992). Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. *Brain Res*, **575**, 93-102.
- Kanyonyo, M., Govaerts, S. J., Hermans, E., Poupaert, J. H. and Lambert, D. M. (1999). 3-Alkyl-(5,5'-diphenyl)imidazolidineones as new cannabinoid receptor ligands. *Bioorg Med Chem Lett*, **9**, 2233-6.
- Kathmann, M., Bauer, U., Schlicker, E. and Gothert, M. (1999). Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. *Naunyn Schmiedebergs Arch Pharmacol*, **359**, 466-70.
- Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K. and Glass, M. (2005). Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk? *Mol Pharmacol*, **67**, 1697-704.
- Lambert, D. M., DiPaolo, F. G., Sonveaux, P., Kanyonyo, M., Govaerts, S. J., Hermans, E., Bueb, J., Delzenne, N. M. and Tschirhart, E. J. (1999). Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. *Biochim Biophys Acta*, **1440**, 266-74.

- Lichtman, A. H., Hawkins, E. G., Griffin, G. and Cravatt, B. F. (2002). Pharmacological activity of Fatty Acid amides is regulated, but not mediated, by Fatty Acid amide hydrolase in vivo. *J Pharmacol Exp Ther*, **302**, 73-9.
- Lin, S., Khanolkar, A. D., Fan, P., Goutopoulos, A., Qin, C., Papahadjis, D. and Makriyannis, A. (1998). Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. *J Med Chem*, **41**, 5353-61.
- Lunn, C. A., Fine, J. S., Rojas-Triana, A., Jackson, J. V., Fan, X., Kung, T. T., Gonsiorek, W., Schwarz, M. A., Lavey, B., Kozlowski, J. A., Narula, S. K., Lundell, D. J., Hipkin, R. W. and Bober, L. A. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. *J Pharmacol Exp Ther*, **316**, 780-8.
- Lynn, A. B. and Herkenham, M. (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. *J Pharmacol Exp Ther*, **268**, 1612-23.
- MacLennan, S. J., Reynen, P. H., Kwan, J. and Bonhaus, D. W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. *Br J Pharmacol*, **124**, 619-22.
- Marchese, G., Casti, P., Ruiu, S., Saba, P., Sanna, A., Casu, G. and Pani, L. (2003). Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. *Br J Pharmacol*, **140**, 520-6.
- Mauler, F., Mittendorf, J., Horvath, E. and De Vry, J. (2002). Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. *J Pharmacol Exp Ther*, **302**, 359-68.
- McAllister, S. D., Rizvi, G., Anavi-Goffer, S., Hurst, D. P., Barnett-Norris, J., Lynch, D. L., Reggio, P. H. and Abood, M. E. (2003). An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. *J Med Chem*, **46**, 5139-52.
- McAllister, S. D., Tao, Q., Barnett-Norris, J., Buehner, K., Hurst, D. P., Guarnieri, F., Reggio, P. H., Nowell Harmon, K. W., Cabral, G. A. and Abood, M. E. (2002). A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. *Biochem Pharmacol*, **63**, 2121-36.
- Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R. and et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol*, **50**, 83-90.
- Muccioli, G. G., Martin, D., Scriba, G. K., Poppitz, W., Poupaert, J. H., Wouters, J. and Lambert, D. M. (2005). Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. *J Med Chem*, **48**, 2509-17.
- Mukherjee, S., Adams, M., Whiteaker, K., Daza, A., Kage, K., Cassar, S., Meyer, M. and Yao, B. B. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. *Eur J Pharmacol*, **505**, 1-9.
- Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature*, **365**, 61-5.

- Nowell, K. W., Pettit, D. A., Cabral, W. A., Zimmerman, H. W., Jr., Abood, M. E. and Cabral, G. A. (1998). High-level expression of the human CB2 cannabinoid receptor using a baculovirus system. *Biochem Pharmacol*, **55**, 1893-905.
- Olson, J. M., Kennedy, S. J. and Cabral, G. A. (2003). Expression of the murine CB2 cannabinoid receptor using a recombinant Semliki Forest virus. *Biochem Pharmacol*, **65**, 1931-42.
- Picone, R. P., Khanolkar, A. D., Xu, W., Ayotte, L. A., Thakur, G. A., Hurst, D. P., Abood, M. E., Reggio, P. H., Fournier, D. J. and Makriyannis, A. (2005). (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. *Mol Pharmacol*, **68**, 1623-35.
- Rhee, M. H., Nevo, I., Bayewitch, M. L., Zagoory, O. and Vogel, Z. (2000). Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor. *J Neurochem*, **75**, 2485-91.
- Rhee, M. H., Nevo, I., Levy, R. and Vogel, Z. (2000). Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor. *FEBS Lett*, **466**, 300-4.
- Rhee, M. H., Vogel, Z., Barg, J., Bayewitch, M., Levy, R., Hanus, L., Breuer, A. and Mechoulam, R. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. *J Med Chem*, **40**, 3228-33.
- Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D. and et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. *FEBS Lett*, **350**, 240-4.
- Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P. and Le Fur, G. (1996). Characterization of two cloned human CB1 cannabinoid receptor isoforms. *J Pharmacol Exp Ther*, **278**, 871-8.
- Rinaldi-Carmona, M., Le Duigou, A., Oustric, D., Barth, F., Bouaboula, M., Carayon, P., Casellas, P. and Le Fur, G. (1998). Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. *J Pharmacol Exp Ther*, **287**, 1038-47.
- Rinaldi-Carmona, M., Pialot, F., Congy, C., Redon, E., Barth, F., Bachy, A., Breliere, J. C., Soubrie, P. and Le Fur, G. (1996). Characterization and distribution of binding sites for [³H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. *Life Sci*, **58**, 1239-47.
- Ryberg, E., Vu, H. K., Larsson, N., Groblewski, T., Hjorth, S., Elebring, T., Sjogren, S. and Greasley, P. J. (2005). Identification and characterisation of a novel splice variant of the human CB1 receptor. *FEBS Lett*, **579**, 259-64.
- Savinainen, J. R., Kokkola, T., Salo, O. M., Poso, A., Jarvinen, T. and Laitinen, J. T. (2005). Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. *Br J Pharmacol*, **145**, 636-45.
- Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. and Kaminski, N. E. (1997). Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. *Toxicol Appl Pharmacol*, **142**, 278-87.
- Shen, C. P., Xiao, J. C., Armstrong, H., Hagmann, W. and Fong, T. M. (2006). F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. *Eur J Pharmacol*, **531**, 41-6.

- Sheskin, T., Hanus, L., Slager, J., Vogel, Z. and Mechoulam, R. (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. *J Med Chem*, **40**, 659-67.
- Shire, D., Calandra, B., Rinaldi-Carmona, M., Oustric, D., Pessegue, B., Bonnin-Cabanne, O., Le Fur, G., Caput, D. and Ferrara, P. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. *Biochim Biophys Acta*, **1307**, 132-6.
- Shoemaker, J. L., Joseph, B. K., Ruckle, M. B., Mayeux, P. R. and Prather, P. L. (2005). The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. *J Pharmacol Exp Ther*, **314**, 868-75.
- Showalter, V. M., Compton, D. R., Martin, B. R. and Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther*, **278**, 989-99.
- Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M. and Metters, K. M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. *Mol Pharmacol*, **48**, 352-61.
- Song, Z. H. and Bonner, T. I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. *Mol Pharmacol*, **49**, 891-6.
- Song, Z. H. and Feng, W. (2002). Absence of a conserved proline and presence of a conserved tyrosine in the CB2 cannabinoid receptor are crucial for its function. *FEBS Lett*, **531**, 290-4.
- Song, Z. H., Slowey, C. A., Hurst, D. P. and Reggio, P. H. (1999). The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). *Mol Pharmacol*, **56**, 834-40.
- Steffens, M., Engler, C., Zentner, J. and Feuerstein, T. J. (2004). Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. *Br J Pharmacol*, **141**, 1193-203.
- Steffens, M., Zentner, J., Honegger, J. and Feuerstein, T. J. (2005). Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. *Biochem Pharmacol*, **69**, 169-78.
- Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. and Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun*, **215**, 89-97.
- Tao, Q. and Abood, M. E. (1998). Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. *J Pharmacol Exp Ther*, **285**, 651-8.
- Tao, Q., McAllister, S. D., Andreassi, J., Nowell, K. W., Cabral, G. A., Hurst, D. P., Bachtel, K., Ekman, M. C., Reggio, P. H. and Abood, M. E. (1999). Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. *Mol Pharmacol*, **55**, 605-13.
- Thomas, B. F., Gilliam, A. F., Burch, D. F., Roche, M. J. and Seltzman, H. H. (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. *J Pharmacol Exp Ther*, **285**, 285-92.
- Thomas, B. F., Wei, X. and Martin, B. R. (1992). Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [³H]11-OH-delta 9-THC-DMH. *J Pharmacol Exp Ther*, **263**, 1383-90.

- Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., Rabadi, L., Rotshteyn, Y., Chaffer, S. M., Turchin, P. I., Elsemore, D. A., Toth, M., Koetzner, L. and Whiteside, G. T. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. *Neuropharmacology*, **48**, 658-72.
- van der Stelt, M., van Kuik, J. A., Bari, M., van Zadelhoff, G., Leeflang, B. R., Veldink, G. A., Finazzi-Agro, A., Vliegenthart, J. F. and Maccarrone, M. (2002). Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J Med Chem*, **45**, 3709-20.
- Vogel, Z., Bayewitch, M., Levy, R., Matusleibovitch, N., Hanus, L., Ben-Shabat, S., Mechoulam, R., Avidor-Reiss, T. and Barg, J. (1994). Binding and functional studies with peripheral and neuronal cannabinoid receptors. *Regul Pept*, **54**, 313-314.
- Welch, S. P., Dunlow, L. D., Patrick, G. S. and Razdan, R. K. (1995). Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. *J Pharmacol Exp Ther*, **273**, 1235-44.